Table 4.
The relationship between plasma TAFI levels among different TAFI genotypes and different clinicopathological parameters of breast cancer patients.
| Patient characteristics |
TAFI level by Thr325Ile genotypes |
||
|---|---|---|---|
| CC |
CT + TT |
Total |
|
| (n = 42) | (n = 108) | (n = 150) | |
| Menopausal state | |||
| Premenopausal | 100 (75–126) | 80 (71–126) | 58 |
| Postmenopausal | 130 (86–156) | 84 (70–150) | 92 |
| First degree family history | |||
| Negative | 102 (75–156) | 86 (70–150) | 140 |
| Positive | 0 | 79.5 (78–93) | 10 |
| Histological type of Breast cancer* | |||
| Duct carcinoma | 102 (86–156) | 79 (70–124) | 110 |
| Lobular carcinoma | 115 (75–156) | 100 (75–175) | 23 |
| Mixed duct and lobular | 94 (86–102) | 120 (86–125) | 10 |
| Poorly differentiated tumor | 143 (130–155) | 120 (100–140) | 7 |
| Biological sub-type of Breast cancer* | |||
| Luminal A | 100 (75–156) | 79.5 (71–124) | 70 |
| Luminal B | 0 | 89.5 (76–120) | 10 |
| Basal-like | 110 (86–156) | 84 (70–107) | 52 |
| HER2+ | 137 (130–145) | 126 (79–150) | 18 |
| Tumor grade | |||
| GI | 0 (0) | 82 (75–100) | 12 |
| GII | 101 (75–156) | 80 (70–124) | 95 |
| GIII | 137 (86–156) | 100 (75–150) | 43 |
| Tumor stage* | |||
| Early (I, IIA and IIB) | 102 (100–126) | 79 (70–124) | 80 |
| Late (IIIA, IIIC and IV) | 115 (75–156) | 95 (71–150) | 70 |
| NPI* | |||
| Good prognosis | 105 (101–110) | 80 (70–100) | 37 |
| Moderate prognosis | 100 (75–156) | 79 (70–124) | 70 |
| Poor prognosis | 137 (86–156) | 100 (75–150) | 43 |
| IHPI* | |||
| Good prognosis | 100 (75–156) | 80 (71–124) | 80 |
| Moderate prognosis | 110 (86–156) | 84 (70–107) | 52 |
| Bad prognosis | 138 (130–145) | 126 (79–150) | 18 |
| Risk of recurrence** | |||
| Intermediate | 130 (100–126) | 100 (79–150) | 100 |
| High | 115 (75–156) | 79 (70–124) | 50 |
TAFI (thrombin-activatable fibrinolysis inhibitor) Ag levels were expressed as percentage of normal pooled plasma (NPP); data are presented as median (range); HER2, human epidermal growth factor receptor 2; NPI, Nottingham Prognostic Index; IHPI, Immunohistochemical Prognostic Index. Comparisons were performed by Kruskal–Wallis test followed by Tukey multiple comparison test for each group in case of more than two subgroup analysis. *, indicates a statistically significant difference P < 0.05. **, indicates statistically significantly difference P < 0.001.